首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1522304

2024 年前列腺癌核子醫學診斷全球市場報告

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2024

出版日期: 2024年07月29日 | 出版商:

The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄

前列腺癌核醫診斷市場規模預計未來幾年將快速成長。到2028年，這一數字將以14.8%的年複合成長率(CAGR)成長至14.9億美元。預測期內的成長受到多種因素的推動，包括前列腺癌盛行率上升、對正子斷層掃描的需求增加、環境永續性意識增強、癌症發生率增加以及持續的數位轉型。這段時期預計的主要趨勢包括產品創新、技術進步、核子醫學掃描術診斷的進步、放射性藥物和影像方式的改進以及創新放射性藥物的開發。

隨著攝護腺癌盛行率預計將增加，攝護腺癌核醫學診斷市場預計將擴大。前列腺癌是一種始於前列腺的癌症，受到老齡化、生活方式改變和遺傳傾向等因素的影響。前列腺癌的核子醫學診斷提供了重要的見解，使臨床醫生能夠為患者提供更準確、更有效的個人化治療。例如，2024 年 1 月，美國癌症協會報告約有 299 萬前列腺癌新病例，並有 35,250 人因此病死亡。此外，2021 年，美國癌症研究所記錄每 10 萬名男性中有 116.5 例新病例。因此，攝護腺癌盛行率的增加是攝護腺癌核醫學診斷市場的關鍵促進因素。

前列腺癌核醫學診斷領域的主要企業正在積極創新診斷影像技術並獲得美國食品藥物管理局（FDA）的批准。 FDA 的許可確保醫療保健提供者和患者能夠針對各種醫療狀況獲得安全有效的診斷測試。例如，2022年3月，瑞士製藥公司諾華宣布推出Pluvic®（镥Lu 177 vipivotide tetraxetan），用於治療診斷為表達前列腺特異性膜抗原陽性（PSMA陽性）的轉移性去勢抗性前列腺癌（mCRPC ）的成年患者。 Pluvicto 將標靶化合物（配體）與治療性放射性同位素結合，為表達 PSMA 的前列腺癌細胞提供精確的癌症治療。

全球前列腺癌核醫診斷市場：按類型、表現和預測，2018-2023、2023-2028、2033
單光子發射電腦斷層掃描 (SPECT)
光子發射電腦斷層掃描 (PET)
全球前列腺癌核醫學診斷市場：按測試類型分類的表現和預測，2018-2023、2023-2028、2033
初步測試
確認測試
全球前列腺癌核醫診斷市場：最終使用者的表現與預測，2018-2023、2023-2028、2033
醫院
診所
其他最終用戶

第 7 章區域/國家分析

全球前列腺癌核醫診斷市場：按地區、表現及預測，2018-2023年、2023-2028年、2033年
全球前列腺癌核醫診斷市場：依國家、績效及預測，2018-2023、2023-2028、2033

第8章亞太市場

第9章中國市場

第10章印度市場

第11章日本市場

第12章澳洲市場

第13章印尼市場

第14章韓國市場

第15章西歐市場

第16章英國市場

第17章德國市場

第18章法國市場

第19章義大利市場

第20章西班牙市場

第21章東歐市場

第22章俄羅斯市場

第23章北美市場

第24章美國市場

第25章加拿大市場

第26章南美洲市場

第27章巴西市場

第28章中東市場

第29章非洲市場

第30章競爭格局及公司概況

攝護腺癌核醫診斷市場：競爭格局
前列腺癌核醫診斷市場：公司簡介
- Cardinal Health
- General Electric
- Bayer AG
- Novartis AG
- Siemens Healthineers AG

第31章其他重大及創新企業

GE Healthcare
Lantheus
CURIUM PHARMA
Telix Pharmaceuticals Ltd.
Eckert & Ziegler AG
Point Biopharma Global Inc.
Point Biopharma
Alliance Medical Ltd.
SHINE Medical Technologies LLC
PETNET Solution
NorthStar Medical Radioisotopes LLC
Global Medical Solutions LLC
Isotope Technologies Garching（ITG）
Jubilant Pharma Limited
Blue Earth Diagnostics Inc.

第32章競爭基準化分析

第 33 章. 競爭對手儀表板

第34章重大併購

第35章前瞻性與潛力分析

第36章附錄

簡介目錄

Product Code: r18457

Prostate cancer nuclear medicine diagnostics involve the utilization of radioactive substances to detect and assess prostate cancer. These diagnostics play a crucial role in the detection, staging, and management of prostate cancer by providing comprehensive functional information regarding the disease's extent and characteristics. The process entails introducing radioactive substances (radiopharmaceuticals) into the body, typically through injection, which emit gamma rays or positrons.

The primary types of prostate cancer nuclear medicine diagnostics include single photon emission computed tomography (SPECT) and positron emission tomography (PET). Single photon emission computed tomography (SPECT) is a nuclear imaging technique that generates detailed three-dimensional images depicting the body's functional processes. These diagnostics encompass various test types, including preliminary and confirmatory tests, and are utilized by various end-users such as hospitals, clinics, and others.

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer nuclear medicine diagnostics market statistics, including prostate cancer nuclear medicine diagnostics industry global market size, regional shares, competitors with a prostate cancer nuclear medicine diagnostics market share, detailed prostate cancer nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. This prostate cancer nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostrate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.75 billion in 2023 to $0.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to several factors, increased demand for PET scans, urbanization, rising disposable income, the need for accurate cancer diagnosis, and an increased emphasis on early detection.

The prostrate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.49 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to several factors, the rising prevalence of prostate cancer, increasing demand for positron emission tomography, growing awareness about environmental sustainability, the increasing frequency of cancers, and the ongoing digital transformation. Major trends expected during this period include product innovation, technological advancements, progress in nuclear medicine imaging, improvements in radiopharmaceuticals and imaging methods, and the development of innovative radiopharmaceuticals.

The anticipated increase in prostate cancer prevalence is expected to drive the expansion of the prostate cancer nuclear medicine diagnostics market. Prostate cancer, a type of cancer occurring in the prostate gland, is influenced by factors such as aging, lifestyle shifts, and genetic predispositions. Nuclear medicine diagnostics for prostate cancer offer crucial insights enabling clinicians to administer more accurate, efficient, and personalized treatment to patients. For instance, in January 2024, the American Cancer Society reported approximately 2.99 million new cases of prostate cancer and 35,250 deaths attributed to the disease. Additionally, in 2021, the National Cancer Institute recorded a rate of 116.5 new cases per 100,000 men annually. Thus, the increasing prevalence of prostate cancer is a significant driver for the prostate cancer nuclear medicine diagnostics market.

Key players in the prostate cancer nuclear medicine diagnostics sector are actively innovating diagnostic imaging technologies and securing approvals from the US Food and Drug Administration (FDA). FDA clearance ensures healthcare providers and patients have access to safe and effective diagnostic tests for various medical conditions. For example, in March 2022, Novartis, a Swiss pharmaceutical company, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen-positive (PSMA-positive). Pluvicto combines a targeting compound (ligand) with a therapeutic radioisotope, delivering precise cancer treatment to prostate cancer cells expressing PSMA.

In March 2023, Life Healthcare Group, a South African healthcare company, acquired TheraMed Nuclear to enhance its diagnostic imaging services, particularly in detecting and treating diseases such as organ dysfunction and cancer. TheraMed Nuclear, based in South Africa, specializes in prostate cancer nuclear medicine diagnostics.

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG , Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC , PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC , Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd. , Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2023. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Single Photon Emission Computed Tomography (SPECT); Photon Emission Computed Tomography (PET)
2) By Test Type: Preliminary Tests; Confirmatory Tests
3) By End User: Hospitals; Clinics; Other End Users
Companies Mentioned: Cardinal Health; General Electric; Bayer AG; Novartis AG; Siemens Healthineers AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

1. Executive Summary

2. Prostate Cancer Nuclear Medicine Diagnostics Market Characteristics

3. Prostate Cancer Nuclear Medicine Diagnostics Market Trends And Strategies

4. Prostate Cancer Nuclear Medicine Diagnostics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Growth

5.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

6.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Single Photon Emission Computed Tomography (SPECT)
Photon Emission Computed Tomography (PET)
6.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Preliminary Tests
Confirmatory Tests
6.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Other End Users

7. Prostate Cancer Nuclear Medicine Diagnostics Market Regional And Country Analysis

7.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market

8.1. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Prostate Cancer Nuclear Medicine Diagnostics Market

9.1. China Prostate Cancer Nuclear Medicine Diagnostics Market Overview
9.2. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Prostate Cancer Nuclear Medicine Diagnostics Market

10.1. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Prostate Cancer Nuclear Medicine Diagnostics Market

11.1. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Overview
11.2. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Prostate Cancer Nuclear Medicine Diagnostics Market

12.1. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market

13.1. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market

14.1. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Overview
14.2. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market

15.1. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
15.2. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Prostate Cancer Nuclear Medicine Diagnostics Market

16.1. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Prostate Cancer Nuclear Medicine Diagnostics Market

17.1. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Prostate Cancer Nuclear Medicine Diagnostics Market

18.1. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Prostate Cancer Nuclear Medicine Diagnostics Market

19.1. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Prostate Cancer Nuclear Medicine Diagnostics Market

20.1. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market

21.1. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
21.2. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Prostate Cancer Nuclear Medicine Diagnostics Market

22.1. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Prostate Cancer Nuclear Medicine Diagnostics Market

23.1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
23.2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Prostate Cancer Nuclear Medicine Diagnostics Market

24.1. USA Prostate Cancer Nuclear Medicine Diagnostics Market Overview
24.2. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Prostate Cancer Nuclear Medicine Diagnostics Market

25.1. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Overview
25.2. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Prostate Cancer Nuclear Medicine Diagnostics Market

26.1. South America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
26.2. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market

27.1. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market

28.1. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market Overview
28.2. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Prostate Cancer Nuclear Medicine Diagnostics Market

29.1. Africa Prostate Cancer Nuclear Medicine Diagnostics Market Overview
29.2. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

30.1. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape
30.2. Prostate Cancer Nuclear Medicine Diagnostics Market Company Profiles
- 30.2.1. Cardinal Health
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. General Electric
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bayer AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Siemens Healthineers AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Prostate Cancer Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

31.1. GE Healthcare
31.2. Lantheus
31.3. CURIUM PHARMA
31.4. Telix Pharmaceuticals Ltd.
31.5. Eckert & Ziegler AG
31.6. Point Biopharma Global Inc.
31.7. Point Biopharma
31.8. Alliance Medical Ltd.
31.9. SHINE Medical Technologies LLC
31.10. PETNET Solution
31.11. NorthStar Medical Radioisotopes LLC
31.12. Global Medical Solutions LLC
31.13. Isotope Technologies Garching (ITG)
31.14. Jubilant Pharma Limited
31.15. Blue Earth Diagnostics Inc.

32. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Benchmarking

33. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Prostate Cancer Nuclear Medicine Diagnostics Market

35. Prostate Cancer Nuclear Medicine Diagnostics Market Future Outlook and Potential Analysis

35.1 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Countries Offering Most New Opportunities
35.2 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Segments Offering Most New Opportunities
35.3 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies